Pharma BD Deal Intelligence
Beam Therapeutics inks $300 million gene-editing collaboration with Pfizer for exclusive four-year research partnership in rare diseases.
Pfizer buys into next-generation gene editing in $300 million deal with Beam Therapeutics combining mRNA/LNP delivery technologies.
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate — Pfizer opted to advance an unnamed liver disease program; Beam…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Pfizer entered a four-year exclusive multi-target research collaboration with Beam Therapeutics (announced Jan 10, 2022) for in vivo base editing programs targeting rare genetic diseases of the liver, muscle, and central nervous system. Pfizer paid $300M upfront, with up to $1.05B in milestone payments (total consideration up to $1.35B) contingent on Pfizer exercising opt-in licenses across the three targets. UPDATE: in December 2025, at the completion of the four-year research period, Pfizer opted in to an exclusive, worldwide license for one liver-targeted base editing development candidate (built on Beam's proprietary liver-targeting LNP); Pfizer assumes all development, manufacturing, regulatory and commercialization responsibility. Beam remains eligible for development, regulatory and commercial milestone payments and retains a right to opt in, at the end of Phase 1/2, to a global co-development and co-commercialization agreement under which Beam and Pfizer would share net profits and costs 35%/65% (Beam/Pfizer). Beam disclosed the opt-in in its Q4/FY2025 results (Feb 24, 2026). Opt-in fee and specific milestone amounts were not disclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Beam Therapeutics Inc. (this deal) | 2022 | $1.4B | 63 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Gene Therapy deals